All In Biotech

Drug Trial Radar · NCT04757974

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

A Two-Part Randomized Study to Evaluate the Relative Bioavailability of Temsavir Following Single Dose Administration of Fostemsavir 600 mg Tablets Compared to Two Fostemsavir 200 mg Tablet Formulations and to Evaluate the Effect of Food on Bioavailability of Selected Fostemsavir 200 mg Tablet Formulation in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Mar 5, 2021

Primary completion

Jul 31, 2021

Study completion Jul 31, 2021

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Feb 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a two-part study. Part 1 will evaluate relative bioavailability of temsavir (TMR) following single dose administration of the reference fostemsavir (FTR) compared to two low-dose ER tablet formulations of FTR. In Part 2, the effect of food on the bioavailability of TMR will be assessed on the selected low-dose ER tablet formulation from Part 1.

Conditions

  • HIV Infections

Interventions

  • Fostemsavir 600 mgDrug

    Fostemsavir tablets will be administered via oral route.

  • Fostemsavir 200 mgDrug

    Fostemsavir tablets will be administered via oral route.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable time point (AUC[0-t]) of temsavirTime frame: Predose (Day 1) until 72 hour post dose
  2. Part 1: AUC from time zero extrapolated to infinite time (AUC[0-infinity]) of temsavirTime frame: Predose (Day 1) until 72 hour post dose
  3. Part 1: Maximum observed plasma concentration (Cmax)Time frame: Predose (Day 1) until 72 hour post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.